CN110537684A - 一种具有治疗肺癌食疗组合物及其制备方法 - Google Patents
一种具有治疗肺癌食疗组合物及其制备方法 Download PDFInfo
- Publication number
- CN110537684A CN110537684A CN201910326917.3A CN201910326917A CN110537684A CN 110537684 A CN110537684 A CN 110537684A CN 201910326917 A CN201910326917 A CN 201910326917A CN 110537684 A CN110537684 A CN 110537684A
- Authority
- CN
- China
- Prior art keywords
- parts
- female carrot
- female
- lung cancer
- carrot
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 104
- 208000020816 lung neoplasm Diseases 0.000 title claims abstract description 85
- 206010058467 Lung neoplasm malignant Diseases 0.000 title claims abstract description 84
- 201000005202 lung cancer Diseases 0.000 title claims abstract description 84
- 238000002560 therapeutic procedure Methods 0.000 title claims abstract description 53
- 238000002360 preparation method Methods 0.000 title claims abstract description 33
- 235000005911 diet Nutrition 0.000 title claims abstract description 28
- 230000000378 dietary effect Effects 0.000 title claims abstract description 27
- 244000000626 Daucus carota Species 0.000 claims abstract description 242
- 235000002767 Daucus carota Nutrition 0.000 claims abstract description 242
- 244000185386 Thladiantha grosvenorii Species 0.000 claims abstract description 86
- 235000011171 Thladiantha grosvenorii Nutrition 0.000 claims abstract description 86
- 240000002853 Nelumbo nucifera Species 0.000 claims abstract description 65
- 235000006508 Nelumbo nucifera Nutrition 0.000 claims abstract description 65
- 235000006510 Nelumbo pentapetala Nutrition 0.000 claims abstract description 65
- 235000008100 Ginkgo biloba Nutrition 0.000 claims abstract description 56
- 235000011201 Ginkgo Nutrition 0.000 claims abstract description 54
- 235000002566 Capsicum Nutrition 0.000 claims abstract description 53
- 239000006002 Pepper Substances 0.000 claims abstract description 53
- 235000016761 Piper aduncum Nutrition 0.000 claims abstract description 53
- 235000017804 Piper guineense Nutrition 0.000 claims abstract description 53
- 235000008184 Piper nigrum Nutrition 0.000 claims abstract description 53
- 239000000463 material Substances 0.000 claims abstract description 41
- 241000222336 Ganoderma Species 0.000 claims abstract description 40
- 238000002156 mixing Methods 0.000 claims abstract description 37
- 244000036905 Benincasa cerifera Species 0.000 claims abstract description 36
- 235000011274 Benincasa cerifera Nutrition 0.000 claims abstract description 36
- 239000002245 particle Substances 0.000 claims abstract description 35
- 241000196324 Embryophyta Species 0.000 claims abstract description 32
- 239000006187 pill Substances 0.000 claims abstract description 30
- 239000011812 mixed powder Substances 0.000 claims abstract description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 67
- 238000007710 freezing Methods 0.000 claims description 40
- 230000008014 freezing Effects 0.000 claims description 40
- 238000000034 method Methods 0.000 claims description 40
- 238000003756 stirring Methods 0.000 claims description 40
- 210000000582 semen Anatomy 0.000 claims description 38
- 239000007788 liquid Substances 0.000 claims description 36
- 239000000843 powder Substances 0.000 claims description 30
- 238000010298 pulverizing process Methods 0.000 claims description 25
- 238000011160 research Methods 0.000 claims description 22
- 230000002829 reductive effect Effects 0.000 claims description 21
- 238000007873 sieving Methods 0.000 claims description 19
- 238000009835 boiling Methods 0.000 claims description 15
- 238000010411 cooking Methods 0.000 claims description 15
- 235000010149 Brassica rapa subsp chinensis Nutrition 0.000 claims description 14
- 235000000536 Brassica rapa subsp pekinensis Nutrition 0.000 claims description 14
- 241000499436 Brassica rapa subsp. pekinensis Species 0.000 claims description 14
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 14
- 239000011259 mixed solution Substances 0.000 claims description 14
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 12
- 235000012907 honey Nutrition 0.000 claims description 12
- 238000005507 spraying Methods 0.000 claims description 12
- 238000009210 therapy by ultrasound Methods 0.000 claims description 12
- 238000004108 freeze drying Methods 0.000 claims description 11
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 10
- 235000013399 edible fruits Nutrition 0.000 claims description 10
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims description 10
- 229940107187 fructooligosaccharide Drugs 0.000 claims description 10
- 239000000832 lactitol Substances 0.000 claims description 10
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 claims description 10
- 235000010448 lactitol Nutrition 0.000 claims description 10
- 229960003451 lactitol Drugs 0.000 claims description 10
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 10
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 10
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 10
- 230000008569 process Effects 0.000 claims description 10
- 235000007882 dietary composition Nutrition 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 7
- 230000006835 compression Effects 0.000 claims description 7
- 238000007906 compression Methods 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 7
- 238000000227 grinding Methods 0.000 claims description 7
- 235000019359 magnesium stearate Nutrition 0.000 claims description 7
- 238000005096 rolling process Methods 0.000 claims description 7
- 238000010025 steaming Methods 0.000 claims description 7
- 229910052757 nitrogen Inorganic materials 0.000 claims description 6
- 239000008213 purified water Substances 0.000 claims description 6
- 238000007711 solidification Methods 0.000 claims description 6
- 230000008023 solidification Effects 0.000 claims description 6
- 239000000243 solution Substances 0.000 claims description 6
- 229940057948 magnesium stearate Drugs 0.000 claims description 3
- 241000218628 Ginkgo Species 0.000 claims 9
- 241000722363 Piper Species 0.000 claims 8
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 230000037213 diet Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 48
- 244000194101 Ginkgo biloba Species 0.000 abstract description 47
- 235000013305 food Nutrition 0.000 abstract description 40
- 208000024891 symptom Diseases 0.000 abstract description 16
- 230000036039 immunity Effects 0.000 abstract description 5
- 244000203593 Piper nigrum Species 0.000 abstract 1
- 238000003825 pressing Methods 0.000 abstract 1
- 240000003889 Piper guineense Species 0.000 description 44
- 210000004072 lung Anatomy 0.000 description 36
- 239000003814 drug Substances 0.000 description 33
- 206010011224 Cough Diseases 0.000 description 29
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 17
- 206010028980 Neoplasm Diseases 0.000 description 17
- 201000011510 cancer Diseases 0.000 description 17
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 14
- 239000011575 calcium Substances 0.000 description 14
- 229910052791 calcium Inorganic materials 0.000 description 14
- 208000002193 Pain Diseases 0.000 description 12
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 12
- 230000006870 function Effects 0.000 description 12
- 230000036407 pain Effects 0.000 description 12
- 239000011591 potassium Substances 0.000 description 12
- 229910052700 potassium Inorganic materials 0.000 description 12
- SUVMJBTUFCVSAD-UHFFFAOYSA-N sulforaphane Chemical compound CS(=O)CCCCN=C=S SUVMJBTUFCVSAD-UHFFFAOYSA-N 0.000 description 12
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 11
- 206010062717 Increased upper airway secretion Diseases 0.000 description 11
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 11
- 208000026435 phlegm Diseases 0.000 description 11
- 235000007686 potassium Nutrition 0.000 description 11
- 235000018102 proteins Nutrition 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 10
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 10
- 241000220259 Raphanus Species 0.000 description 10
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 10
- 208000006673 asthma Diseases 0.000 description 10
- 239000011574 phosphorus Substances 0.000 description 10
- 229910052698 phosphorus Inorganic materials 0.000 description 10
- 235000014786 phosphorus Nutrition 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 238000002512 chemotherapy Methods 0.000 description 9
- 235000009508 confectionery Nutrition 0.000 description 9
- 230000001976 improved effect Effects 0.000 description 9
- 210000004185 liver Anatomy 0.000 description 9
- 238000001959 radiotherapy Methods 0.000 description 9
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 8
- 150000001720 carbohydrates Chemical class 0.000 description 8
- 235000014633 carbohydrates Nutrition 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 239000000796 flavoring agent Substances 0.000 description 8
- 235000019634 flavors Nutrition 0.000 description 8
- 229910052742 iron Inorganic materials 0.000 description 8
- 229910052711 selenium Inorganic materials 0.000 description 8
- 239000011669 selenium Substances 0.000 description 8
- 229940088594 vitamin Drugs 0.000 description 8
- 229930003231 vitamin Natural products 0.000 description 8
- 235000013343 vitamin Nutrition 0.000 description 8
- 239000011782 vitamin Substances 0.000 description 8
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 7
- 210000003734 kidney Anatomy 0.000 description 7
- 239000011777 magnesium Substances 0.000 description 7
- 229910052749 magnesium Inorganic materials 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 229910052708 sodium Inorganic materials 0.000 description 7
- 239000011734 sodium Substances 0.000 description 7
- 235000019640 taste Nutrition 0.000 description 7
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 6
- SUVMJBTUFCVSAD-JTQLQIEISA-N 4-Methylsulfinylbutyl isothiocyanate Natural products C[S@](=O)CCCCN=C=S SUVMJBTUFCVSAD-JTQLQIEISA-N 0.000 description 6
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 240000008397 Ganoderma lucidum Species 0.000 description 6
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 6
- 206010027476 Metastases Diseases 0.000 description 6
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 6
- 206010036790 Productive cough Diseases 0.000 description 6
- 229930003448 Vitamin K Natural products 0.000 description 6
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- 230000001093 anti-cancer Effects 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 206010061428 decreased appetite Diseases 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 239000008176 lyophilized powder Substances 0.000 description 6
- 235000016709 nutrition Nutrition 0.000 description 6
- 244000045947 parasite Species 0.000 description 6
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 235000019192 riboflavin Nutrition 0.000 description 6
- 239000002151 riboflavin Substances 0.000 description 6
- 229960002477 riboflavin Drugs 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- 229960005559 sulforaphane Drugs 0.000 description 6
- 235000015487 sulforaphane Nutrition 0.000 description 6
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 6
- 229960003495 thiamine Drugs 0.000 description 6
- 231100000331 toxic Toxicity 0.000 description 6
- 230000002588 toxic effect Effects 0.000 description 6
- 235000019168 vitamin K Nutrition 0.000 description 6
- 239000011712 vitamin K Substances 0.000 description 6
- 150000003721 vitamin K derivatives Chemical class 0.000 description 6
- 229940046010 vitamin k Drugs 0.000 description 6
- 239000011701 zinc Substances 0.000 description 6
- 229910052725 zinc Inorganic materials 0.000 description 6
- 235000016804 zinc Nutrition 0.000 description 6
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 230000000844 anti-bacterial effect Effects 0.000 description 5
- 229960005070 ascorbic acid Drugs 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 5
- 210000000038 chest Anatomy 0.000 description 5
- 229910052802 copper Inorganic materials 0.000 description 5
- 239000010949 copper Substances 0.000 description 5
- 235000019197 fats Nutrition 0.000 description 5
- 239000000835 fiber Substances 0.000 description 5
- 230000009401 metastasis Effects 0.000 description 5
- 235000001968 nicotinic acid Nutrition 0.000 description 5
- 229960003512 nicotinic acid Drugs 0.000 description 5
- 239000011664 nicotinic acid Substances 0.000 description 5
- 235000015097 nutrients Nutrition 0.000 description 5
- 238000004321 preservation Methods 0.000 description 5
- 210000003802 sputum Anatomy 0.000 description 5
- 208000024794 sputum Diseases 0.000 description 5
- 210000002700 urine Anatomy 0.000 description 5
- 150000003722 vitamin derivatives Chemical class 0.000 description 5
- 206010008479 Chest Pain Diseases 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 4
- 206010013952 Dysphonia Diseases 0.000 description 4
- 208000000059 Dyspnea Diseases 0.000 description 4
- 206010013975 Dyspnoeas Diseases 0.000 description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 4
- 208000003251 Pruritus Diseases 0.000 description 4
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 4
- 206010047700 Vomiting Diseases 0.000 description 4
- 244000089698 Zanthoxylum simulans Species 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 235000010323 ascorbic acid Nutrition 0.000 description 4
- 239000011668 ascorbic acid Substances 0.000 description 4
- 210000001124 body fluid Anatomy 0.000 description 4
- 239000010839 body fluid Substances 0.000 description 4
- 150000001746 carotenes Chemical class 0.000 description 4
- 235000005473 carotenes Nutrition 0.000 description 4
- 238000004140 cleaning Methods 0.000 description 4
- 235000013325 dietary fiber Nutrition 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000035764 nutrition Effects 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 235000019157 thiamine Nutrition 0.000 description 4
- 239000011721 thiamine Substances 0.000 description 4
- 230000035922 thirst Effects 0.000 description 4
- 239000011573 trace mineral Substances 0.000 description 4
- 235000013619 trace mineral Nutrition 0.000 description 4
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 4
- 238000010792 warming Methods 0.000 description 4
- YLKVIMNNMLKUGJ-FPLPWBNLSA-N (15:1)-Cardanol Chemical compound CCCCCC\C=C/CCCCCCCC1=CC=CC(O)=C1 YLKVIMNNMLKUGJ-FPLPWBNLSA-N 0.000 description 3
- YXHVCZZLWZYHSA-UHFFFAOYSA-N (Z)-6-[8-pentadecenyl]salicylic acid Natural products CCCCCCC=CCCCCCCCC1=CC=CC(O)=C1C(O)=O YXHVCZZLWZYHSA-UHFFFAOYSA-N 0.000 description 3
- YLKVIMNNMLKUGJ-UHFFFAOYSA-N 3-Delta8-pentadecenylphenol Natural products CCCCCCC=CCCCCCCCC1=CC=CC(O)=C1 YLKVIMNNMLKUGJ-UHFFFAOYSA-N 0.000 description 3
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- YXHVCZZLWZYHSA-FPLPWBNLSA-N Ginkgoic acid Chemical compound CCCCCC\C=C/CCCCCCCC1=CC=CC(O)=C1C(O)=O YXHVCZZLWZYHSA-FPLPWBNLSA-N 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- 206010018612 Gonorrhoea Diseases 0.000 description 3
- 208000010473 Hoarseness Diseases 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 206010033557 Palpitations Diseases 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 3
- 208000002474 Tinea Diseases 0.000 description 3
- 241000130764 Tinea Species 0.000 description 3
- 229930003427 Vitamin E Natural products 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 206010000269 abscess Diseases 0.000 description 3
- 208000022531 anorexia Diseases 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 3
- 235000013922 glutamic acid Nutrition 0.000 description 3
- 239000004220 glutamic acid Substances 0.000 description 3
- 208000001786 gonorrhea Diseases 0.000 description 3
- 208000014617 hemorrhoid Diseases 0.000 description 3
- 230000036737 immune function Effects 0.000 description 3
- 206010022437 insomnia Diseases 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 230000007803 itching Effects 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 206010029410 night sweats Diseases 0.000 description 3
- 230000036565 night sweats Effects 0.000 description 3
- 229960003975 potassium Drugs 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 3
- 238000010791 quenching Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 230000010415 tropism Effects 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 235000019165 vitamin E Nutrition 0.000 description 3
- 229940046009 vitamin E Drugs 0.000 description 3
- 239000011709 vitamin E Substances 0.000 description 3
- AAWZDTNXLSGCEK-LNVDRNJUSA-N (3r,5r)-1,3,4,5-tetrahydroxycyclohexane-1-carboxylic acid Chemical compound O[C@@H]1CC(O)(C(O)=O)C[C@@H](O)C1O AAWZDTNXLSGCEK-LNVDRNJUSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- QXNWZXMBUKUYMD-ITUXNECMSA-N 4-keto-beta-carotene Chemical compound CC=1C(=O)CCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C QXNWZXMBUKUYMD-ITUXNECMSA-N 0.000 description 2
- BGEBZHIAGXMEMV-UHFFFAOYSA-N 5-methoxypsoralen Chemical compound O1C(=O)C=CC2=C1C=C1OC=CC1=C2OC BGEBZHIAGXMEMV-UHFFFAOYSA-N 0.000 description 2
- 206010000087 Abdominal pain upper Diseases 0.000 description 2
- 201000004384 Alopecia Diseases 0.000 description 2
- 102100023635 Alpha-fetoprotein Human genes 0.000 description 2
- 208000008035 Back Pain Diseases 0.000 description 2
- 206010006482 Bronchospasm Diseases 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 2
- AAWZDTNXLSGCEK-UHFFFAOYSA-N Cordycepinsaeure Natural products OC1CC(O)(C(O)=O)CC(O)C1O AAWZDTNXLSGCEK-UHFFFAOYSA-N 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- 239000004367 Lipase Substances 0.000 description 2
- 102000004882 Lipase Human genes 0.000 description 2
- 108090001060 Lipase Proteins 0.000 description 2
- 208000003351 Melanosis Diseases 0.000 description 2
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 2
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 2
- 102000004960 NAD(P)H dehydrogenase (quinone) Human genes 0.000 description 2
- 108020000284 NAD(P)H dehydrogenase (quinone) Proteins 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 206010068319 Oropharyngeal pain Diseases 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 201000007100 Pharyngitis Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 208000001431 Psychomotor Agitation Diseases 0.000 description 2
- AAWZDTNXLSGCEK-ZHQZDSKASA-N Quinic acid Natural products O[C@H]1CC(O)(C(O)=O)C[C@H](O)C1O AAWZDTNXLSGCEK-ZHQZDSKASA-N 0.000 description 2
- 206010038743 Restlessness Diseases 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 206010041497 Spermatorrhoea Diseases 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 206010042674 Swelling Diseases 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- 229930003270 Vitamin B Natural products 0.000 description 2
- 229930003451 Vitamin B1 Natural products 0.000 description 2
- 206010047601 Vitamin B1 deficiency Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 150000003797 alkaloid derivatives Chemical class 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 231100000360 alopecia Toxicity 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 230000002429 anti-coagulating effect Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 230000006793 arrhythmia Effects 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 208000002894 beriberi Diseases 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 230000005907 cancer growth Effects 0.000 description 2
- FDSDTBUPSURDBL-LOFNIBRQSA-N canthaxanthin Chemical compound CC=1C(=O)CCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)CCC1(C)C FDSDTBUPSURDBL-LOFNIBRQSA-N 0.000 description 2
- 231100000357 carcinogen Toxicity 0.000 description 2
- 239000003183 carcinogenic agent Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 229960002598 fumaric acid Drugs 0.000 description 2
- 235000011087 fumaric acid Nutrition 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 230000002439 hemostatic effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 235000019421 lipase Nutrition 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 201000003453 lung abscess Diseases 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 229940099690 malic acid Drugs 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 239000002398 materia medica Substances 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 239000002366 mineral element Substances 0.000 description 2
- 229910052750 molybdenum Inorganic materials 0.000 description 2
- 239000011733 molybdenum Substances 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 235000006408 oxalic acid Nutrition 0.000 description 2
- 229940116315 oxalic acid Drugs 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000002040 relaxant effect Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 238000002603 single-photon emission computed tomography Methods 0.000 description 2
- 210000001562 sternum Anatomy 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 235000019605 sweet taste sensations Nutrition 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000002936 tranquilizing effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 235000019156 vitamin B Nutrition 0.000 description 2
- 239000011720 vitamin B Substances 0.000 description 2
- 235000010374 vitamin B1 Nutrition 0.000 description 2
- 239000011691 vitamin B1 Substances 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 1
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- 235000007173 Abies balsamea Nutrition 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010002953 Aphonia Diseases 0.000 description 1
- 235000007650 Aralia spinosa Nutrition 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000004857 Balsam Substances 0.000 description 1
- DBMJZOMNXBSRED-UHFFFAOYSA-N Bergamottin Natural products O1C(=O)C=CC2=C1C=C1OC=CC1=C2OCC=C(C)CCC=C(C)C DBMJZOMNXBSRED-UHFFFAOYSA-N 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 description 1
- 235000017647 Brassica oleracea var italica Nutrition 0.000 description 1
- 240000003259 Brassica oleracea var. botrytis Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000009079 Bronchial Spasm Diseases 0.000 description 1
- 208000014181 Bronchial disease Diseases 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 108010008629 CA-125 Antigen Proteins 0.000 description 1
- 102000007269 CA-125 Antigen Human genes 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 241000186227 Corynebacterium diphtheriae Species 0.000 description 1
- 241001337994 Cryptococcus <scale insect> Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 102000011724 DNA Repair Enzymes Human genes 0.000 description 1
- 108010076525 DNA Repair Enzymes Proteins 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- 206010013453 Disseminated tuberculosis Diseases 0.000 description 1
- 206010013911 Dysgeusia Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 206010014970 Ephelides Diseases 0.000 description 1
- 206010053155 Epigastric discomfort Diseases 0.000 description 1
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 102000008857 Ferritin Human genes 0.000 description 1
- 108050000784 Ferritin Proteins 0.000 description 1
- 238000008416 Ferritin Methods 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 244000018716 Impatiens biflora Species 0.000 description 1
- 208000019637 Infantile Diarrhea Diseases 0.000 description 1
- 206010061217 Infestation Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 240000008415 Lactuca sativa Species 0.000 description 1
- 235000003228 Lactuca sativa Nutrition 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- XCUCMLUTCAKSOZ-FIRIVFDPSA-N Liensinine Chemical compound C([C@@H]1C=2C=C(C(=CC=2CCN1C)OC)OC=1C(O)=CC=C(C=1)C[C@H]1N(C)CCC=2C=C(C(=CC=21)OC)OC)C1=CC=C(O)C=C1 XCUCMLUTCAKSOZ-FIRIVFDPSA-N 0.000 description 1
- XCUCMLUTCAKSOZ-JSOSNVBQSA-N Liensinine Natural products C([C@@H]1C=2C=C(C(=CC=2CCN1C)OC)OC=1C(O)=CC=C(C=1)C[C@@H]1N(C)CCC=2C=C(C(=CC=21)OC)OC)C1=CC=C(O)C=C1 XCUCMLUTCAKSOZ-JSOSNVBQSA-N 0.000 description 1
- 206010024642 Listless Diseases 0.000 description 1
- 208000032912 Local swelling Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 206010025182 Lymph node pain Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 201000006836 Miliary Tuberculosis Diseases 0.000 description 1
- 102000006833 Multifunctional Enzymes Human genes 0.000 description 1
- 108010047290 Multifunctional Enzymes Proteins 0.000 description 1
- 206010028391 Musculoskeletal Pain Diseases 0.000 description 1
- 102100030856 Myoglobin Human genes 0.000 description 1
- 108010062374 Myoglobin Proteins 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 206010059013 Nocturnal emission Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 208000000114 Pain Threshold Diseases 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- OOUTWVMJGMVRQF-DOYZGLONSA-N Phoenicoxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)C(=O)C(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)C(=O)CCC2(C)C OOUTWVMJGMVRQF-DOYZGLONSA-N 0.000 description 1
- 208000002151 Pleural effusion Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 208000019155 Radiation injury Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 208000007613 Shoulder Pain Diseases 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 206010040925 Skin striae Diseases 0.000 description 1
- 206010071051 Soft tissue mass Diseases 0.000 description 1
- 235000009337 Spinacia oleracea Nutrition 0.000 description 1
- 244000300264 Spinacia oleracea Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 206010062129 Tongue neoplasm Diseases 0.000 description 1
- 206010044302 Tracheitis Diseases 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 241000219094 Vitaceae Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 241000949456 Zanthoxylum Species 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000002082 anti-convulsion Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 201000009361 ascariasis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- KGZDKFWCIPZMRK-UHFFFAOYSA-N bergapten Natural products COC1C2=C(Cc3ccoc13)C=CC(=O)O2 KGZDKFWCIPZMRK-UHFFFAOYSA-N 0.000 description 1
- 229960002045 bergapten Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 230000007885 bronchoconstriction Effects 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 235000012682 canthaxanthin Nutrition 0.000 description 1
- 239000001659 canthaxanthin Substances 0.000 description 1
- 229940008033 canthaxanthin Drugs 0.000 description 1
- 230000003177 cardiotonic effect Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000002485 combustion reaction Methods 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- YXPMCBGFLULSGQ-YHEDCBSUSA-N echinenone Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(=O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CCCC2(C)C YXPMCBGFLULSGQ-YHEDCBSUSA-N 0.000 description 1
- 235000006932 echinenone Nutrition 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000000369 enteropathogenic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000021022 fresh fruits Nutrition 0.000 description 1
- 235000013569 fruit product Nutrition 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000021021 grapes Nutrition 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 208000013210 hematogenous Diseases 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 208000027498 hoarse voice Diseases 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000012216 imaging agent Substances 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 208000017971 listlessness Diseases 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 208000025036 lymphosarcoma Diseases 0.000 description 1
- 229940091250 magnesium supplement Drugs 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 210000005015 mediastinal lymph node Anatomy 0.000 description 1
- 210000001370 mediastinum Anatomy 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000005311 nuclear magnetism Effects 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- -1 p-carotene Chemical compound 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000037040 pain threshold Effects 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 201000001219 parotid gland cancer Diseases 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000021251 pulses Nutrition 0.000 description 1
- 235000019633 pungent taste Nutrition 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000001533 respiratory mucosa Anatomy 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000000779 thoracic wall Anatomy 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 201000006134 tongue cancer Diseases 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/09—Mashed or comminuted products, e.g. pulp, purée, sauce, or products made therefrom, e.g. snacks
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L25/00—Food consisting mainly of nutmeat or seeds; Preparation or treatment thereof
- A23L25/30—Mashed or comminuted products, e.g. pulp, pastes, meal, powders; Products made therefrom, e.g. blocks, flakes, snacks; Liquid or semi-liquid products
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L31/00—Edible extracts or preparations of fungi; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/62—Nymphaeaceae (Water-lily family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/758—Zanthoxylum, e.g. pricklyash
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Botany (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明属于食疗领域,尤其涉及一种具有治疗肺癌食疗组合物及其制备方法;具体为一种具有治疗肺癌作用的特殊医疗用途配方食疗产品。该食疗组合物按照重量份包括以下组分:雌性红萝卜16~30份,雌性红萝卜缨子16~30份,雌性红萝卜与雌性红萝卜缨子草木灰16~30份,无花果3~10份,莲子5~10份,罗汉果4~15份,冬瓜子3~5份,灵芝4~8份,白果1~5份,花椒2~4份。所述的食疗组合物制备方法主要步骤是选材,制成混合粉末颗粒,物料处理,物料混合,压制成片或丸剂。本发明食疗组合物在治疗肺癌上效果显著,可以缩小病灶,减轻症状,提升机体免疫力,延长生存期,提高病人生活质量。
Description
技术领域
本发明属于食疗领域,尤其涉及一种具有治疗肺癌食疗组合物及其制备方法。
背景技术
癌症是世界难题,肺癌是目前人类的第一大杀手,一般早期很难被发现的,发现以后中晚期的阶段比较多的,尤其是中晚期,治愈率很低。肺癌常用治疗手段主要是放化疗、手术和中药。其中中药治疗具有举足轻重的作用,中医药治疗适应于肺癌各个阶段、各种类型的治疗。如何提高肺癌治愈率,治疗方法很关键,选择正确的治疗方法是肺癌治愈重点。肺癌治疗方法有手术、放化疗、靶向治疗,但每一种治疗方法都有其一定的弊端。手术治疗是肺癌的常规方式,通常在病情早期起到很好的作用,但难以清除微小病灶,其复发率非常高,如果再次复发转移会加快病情导致死亡。
放疗和化疗虽能有效杀灭肿瘤细胞,但对患者体内正常细胞一定的破坏,还会存在一定的副作用,如脱发、恶心呕吐、食欲不振等不良反应。
世界卫生组织提出:21世纪人类要寻找药物以外的治疗方式,经过多年的研究和临床试验,采用食疗治疗肺癌作用的特殊医疗用途配方食疗产品,在治疗肺癌效果显著,可以缩小病灶,减轻症状,提升机体免疫力,延长生存期,提高病人生活质量。
发明内容
发明目的:
针对现有技术存在的技术问题,本发明提供一种具有治疗肺癌的食疗组合物及其制备方法;该食疗组合物是一种具有治疗肺癌作用的特殊医疗用途的食疗配方。
技术方案:
一种具有治疗肺癌食疗组合物,按照重量份包括以下组分:雌性红萝卜16~30份,雌性红萝卜缨子16~30份,雌性红萝卜与雌性红萝卜缨子草木灰16~30份,无花果3~10份,莲子5~10份,罗汉果4~15份,冬瓜子3~5份,灵芝4~8份,白果1~5份,花椒2~4份。
具有治疗肺癌食疗组合物的制备方法,该制备方法包括如下步骤:
步骤一:选材:雌性红萝卜选用由沈阳绿星大白菜研究所出品的“雄性不育系”三系杂交雌性红萝卜;雌性红萝卜缨子采用沈阳绿星大白菜研究所出品的“雄性不育系”三系杂交雌性红萝卜缨子;
步骤二:制成混合粉末颗粒:将雌性红萝卜和雌性红萝卜缨子进行混合冷冻,得到雌性红萝卜和雌性红萝卜缨子混合的粉末颗粒;
步骤三:物料处理:将无花果、灵芝分别粉碎、过筛;将白果、冬瓜子一起炒制,炒制后再粉碎;将莲子、花椒、罗汉果的果肉和果壳一起加水煮制成粘稠状液体,取出莲子、罗汉果果肉进行初次蒸制,莲子变软,碾碎后并放回粘稠状液体中,再用少量水对罗汉果果肉和花椒进行二次煮制,煮制后去掉花椒;
步骤四:物料混合:边搅拌边将炒制后的白果和冬瓜子粉末加入粘稠状液体中,并将软烂的罗汉果果肉和二次煮制的水以及粉碎后的无花果、灵芝的加入进去,继续搅拌,再加入雌性红萝卜与雌性红萝卜缨子草木灰,最后将雌性红萝卜和雌性红萝卜缨子混合的粉末颗粒缓慢加入,充分搅拌均匀,得到面团状组合物;
步骤五:压制成片或丸剂:将步骤四中的面团状组合物加入乳糖醇、微晶纤维素和低聚果糖醇,及面团状组合物重量0.1%~5%的硬脂酸镁,混合均匀压片,得到压片;
丸剂:将步骤四中的面团状组合物掺入适量蜂蜜,搓丸,得到丸剂。
本发明各原料的药性分析。
一、雌性红萝卜
雌性红萝卜的食疗作用:
【功效】雌性红萝卜,亦名莱菔,味辛、甘,性微温,入肺、胃二经,其种子、鲜根、叶均可入药。
雌性红萝卜具有清热解毒、润肺止咳、化痰祛浊、生津止渴、滋阴补肾、疏肝理气,健胃消食等。
特别是雌性红萝卜具有超强促进肝、肾代谢功能的作用,它能快速启动肝肾自愈系统,具有超强的疏肝理气,入肺经,肺主皮毛,是补脾益气和补肾纳气用途的食品。
现代医学研究表明:
“东北雌性红萝卜”内有丰富的“萝卜硫素”,萝卜硫素对这种天然化合物能快速启动人体的自愈系统、排毒系统、调理五脏平衡、修复受损器官,具有抗癌作用。
萝卜硫素是一种多功能酶诱导物,可诱导机体产生Ⅱ型解毒酶一谷胱甘肽转移酶(GST)和醌还原酶(QR),此酶能中和可疑致癌物质,防止致癌物质破坏健康细胞内的遗传因子,从而起到抗癌作用,使癌细胞的恶性增殖得以控制,能有效地抑制包括结肠癌,胃癌,肺癌,前列腺癌,肝癌,结肠癌,黑色素瘤和神经母细胞瘤等移种人体肿瘤细胞生长。且具有抗癌作用强,毒副作用低,生物学性质稳定,可用于治疗和预防各种恶性肿瘤。
二、雌性红萝卜缨子
【功效】雌性红萝卜缨子又叫莱菔叶,雌性红萝缨子营养非常丰富,如维生素K的含量高于其他食品,雌性红萝卜缨子是人体摄取天然维生素K的最佳食品,钙含量是菠菜的4倍,铁质含量是鳗鱼的22倍,维生素B1是豆豉的5倍,维生素含量是牛肉4倍,还含有钼及膳食纤维。
同时,雌性红萝卜与雌性红萝卜缨子草木灰为碱性,可以维持整个食疗组合物的碱性环境,还含有丰富的微量元素,除了含有丰富的钾元素外,还含有钙、镁、硅、硫、铁、锰、铜、锌、硼、钼等微量营养元素,本发明将多余的雌性红萝卜缨子进行了二次利用,生产的雌性红萝卜和雌性红萝卜缨子得到充分利用,大大的提高了食疗组合物的经济效益、减小生产的成本,造福广大患者。
三、无花果
【功效】功效作用
无花果含有丰富蛋白质、酶类、维生素和多种微量元素等,尤其是VC的含量最达葡萄的二十倍。无花果既是营养丰富且全面的风味水果,又是一种中药材,叶果根茎全株都能入药。
《本草纲目》上记载:“无花果味甘平,无毒,主开胃、止泄痢、治五痔、咽喉痛”。
无花果含水量高达百分之八十,还含有蛋白质、丙乙酸、脂肪、琥珀酸、粗纤维、碳水化合物、灰分、胡萝卜素、硫胺素、苹果酸、核黄素、延胡索酸、尼克酸、抗坏血酸、维生素E类、草酸、钾、奎宁酸、钠、脂肪酶、钙、镁、铁、锰、锌、铜、磷、硒、柠檬酸及蛋白酶等人体必需的营养素,是一种不可小视、老少皆宜的果品。
四、莲子的功效与作用
1、防癌抗癌:莲子善于补五脏不足,通利十二经脉气血,使气血畅而不腐,莲子所含氧化黄心树宁碱对鼻咽癌有抑制作用,这一切,构成了莲子的防癌抗癌的营养保健功能。
2、清心、祛斑:带心莲子能清心火,祛除雀斑,然不可久煎。
3、强心安神:莲子芯所含生物碱具有显著的强心作用,莲芯碱则有较强抗钙及抗心律不齐的作用。莲子能够帮助防癌抗癌。莲子中含有的氧化黄心树宁碱,丰富的蛋白质、脂肪、碳水化合物、钙、磷、钾等,具有补脾、益肺、养心、益肾和固肠等作用,适用于心悸、失眠、体虚、遗精、白带过多、慢性腹症等症,中老年人、体虚者、食欲不振者可多食用。
五、罗汉果功效
性味归经:性凉,味甘。归肺、大肠经。
功能主治:清热润肺,止咳,利咽,滑肠通便。用于肺火燥咳,咽痛失音,肠燥便秘。
罗汉果味甘性凉,归肺、大肠经,有润肺止咳,生津止渴的功效,适用于肺热或肺燥咳嗽,百日咳及暑热伤津口渴等,此外还有润肠通便的功效。
六、冬瓜子功效
①《本经》:"味甘,平。"
②《别录》:"寒,无毒。"
归经《得配本草》:"入足厥阴经。"
润肺,化痰,消痈,利水。治痰热咳嗽,肺痈,肠痈,淋病,水肿,脚气,痔疮,鼻面酒皶。
七、灵芝功能主治
1、咳喘痰多。该品味甘能补,性平偏温,入肺经,补益肺气,温肺化痰,止咳平喘,常可治痰饮证,见形寒咳嗽、痰多气喘者,尤其对痰湿型或虚寒型疗效较好。
2、心神不宁,失眠,惊悸。该品味甘性平,入心经,能补心血、益心气、安心神,故可用治气血不足、心神失养所致的心神不宁、失眠、惊悸、多梦、健忘、体倦神疲、食少等症。
3、虚劳症。该品有补养气血作用,故常用治虚劳短气、不思饮食、手足逆冷、或烦躁口干等症,
八、白果的功效与作用
白果味甘,微苦、涩,性温,有小毒。能温肺益气,定喘咳,缩小便,止带滞,止泻,益脾。
银杏还可以保护肝脏、减少心律不齐、防止过敏反应中致命性的支气管收缩,还可以应用于对付哮喘、移植排异、心肌梗塞、中风、器官保护和透析。
九、花椒
【功效】花椒归脾经、胃经、肾经,花椒可以温中止痛,花椒用作中药,性温,味辛,有温中散寒、健胃、除湿、止痛、杀虫、解毒、理气、止痒、祛腥等功效;
研究表明,花椒还具有以下确切医疗作用:
1、湿疹瘙痒,抑菌作用。花椒能够加速各种真菌细胞的死亡,对深部真菌具有一定的抑制和杀灭作用哦。
2、杀虫止痒,驱虫作用。花椒中所含挥发油在保温的任氏液中能够使蛔虫严重中毒。因此花椒具有驱虫的功效。
3、温中止痛,镇痛作用。花椒的功效与作用比较多,它还可以降低受伤部位疼痛感,如龋齿牙痛等。
4、利于消化,除湿止泻。花椒有利于人体消化系统。除此以外,花椒还可以治疗因溃疡形成和腹泻、恶心、呕吐等多种症状。
5、抗凝血和止血作用。花椒所含的佛手柑内酯物质具有一定的对抗肝素的抗凝血作用和止血作用。在民间,有的人将花椒水擦点在伤口的周围,可以很快的止血。
本发明的优点及有益效果:
本发明的食疗配方是在东北雌性红萝卜、东北雌性红萝卜缨子及无花果、罗汉果等药食同源基础上研究发明的,据中科院营养检测报告显示:100%纯东北雌性红萝卜跟普通萝卜相比较,钾高出25.8倍、钙高出2.3倍、磷高出2倍、硒高出3.1倍;其中,钾就有调节人体酸碱平衡;钙是酶的激活剂,是人体的生命之源,是人体含量最丰富的无机元素。钙离子对人体内的酶反应有激活作用。酶是人体各种物质代谢过程的催化剂,是人体一种重要的生命物质,钙缺乏即会影响正常的生理代谢过程。
钙离子对人体内分泌腺激素的分泌有决定性作用,对维持循环、呼吸、消化、泌尿、神经、内分泌、生殖等系统器官的功能至关重要。;磷可以快速提高人体自愈力,促进受损器官的修复;硒被科学家称之为人体微量元素中的“抗癌之王”它具有抗氧化作用,能延缓衰老乃至预防某些慢性疾病的发生,硒是维持人体正常免疫功能必备的物质,硒还是人体DNA修复酶的激活素。大量研究证明,雌性红萝卜缨子的营养价值在很多方面高于根;现代研究表明,雌性红萝卜缨子所含维生素C的含量比根高出2倍以上;矿物质元素中的钙、镁、铁、锌以及核黄素、叶酸等含量高出根的3-10倍;尤其是维生素K的含量更是远远高于其他食物,所以说萝卜缨子是人体摄取天然维生素K的最佳食品,维生素k属维生素类药物,是肝脏合成因子Ⅱ、Ⅶ、Ⅸ、Ⅹ所必须的物质。 可缓解支气管痉挛。雌性红萝卜缨子的维生素K含量最高;它所含有的维生素A的含量是西兰花的3倍;雌性红萝卜缨子的膳食纤维含量很高,可以帮助消化,理气、健胃,有润肤养颜的作用。维生素A可以增强人体呼吸道黏膜的抗病能力,将感冒、气管炎、肺炎等冬季高发病降到最低程度。
本发明添加了具有抗癌,清毒健胃、润肺止咳、清热消肿解毒功效的无花果,无花果含水量高达百分之八十,还含有蛋白质、丙乙酸、脂肪、琥珀酸、粗纤维、碳水化合物、灰分、胡萝卜素、硫胺素、苹果酸、核黄素、延胡索酸、尼克酸、抗坏血酸、维生素E类、草酸、钾、奎宁酸、钠、脂肪酶、钙、镁、铁、锰、锌、铜、磷、硒、柠檬酸及蛋白酶等人体必需的营养素,无花果实乳汁对腺癌,肉瘤,乳瘤,白血病,淋巴肉瘤均有抑制作用。临床用治各类恶性肿瘤,包括肺癌,腮腺癌,胃癌,肝癌,结肠癌,肾癌,舌癌,等。
同时加入具有营养价值高,可以抗癌,润肺止咳,生津止渴,肺热或肺燥咳嗽,润肠通便的罗汉果,其蛋白质、氨基酸 含蛋白质7.1%-7.8%。在其水解物中,除色氨酸未被测定外,18种氨基酸齐全。在测定的氨基酸中,含量较高的有谷氨酸(108.2-113.3mg/kg)、天冬氨酸(93.9-112.5mg/kg)、缬氨酸(52.5-55.5mg/kg)、丙氨酸(49.9-66.8mg/kg)、亮氨酸(48.5-56.7mg/kg)。谷氨酸是人体中需要量最大的非必需氨基酸,是合成谷胱甘肽的重要原料,可见,罗汉果具有较高的营养价值。
罗汉果果实中含有24种无机元素,其中人体必需的微量元素和广泛元素有16种,含量较高的元素有钾(12290mg/kg)、钙(667mg/kg)、镁(550mg/kg)。罗汉果中含有的硒达到0.186mg/kg,是粮食的2倍-4倍,而元素硒在冠心病防治、抗衰老、抗癌方面有较好的疗效。
冬瓜子具有润肺,化痰,消痈,利水。治痰热咳嗽,肺痈,肠痈,淋病,水肿,脚气,痔疮,鼻面酒皶。
每100g鲜冬瓜中含有蛋白质0.3g,碳水化合物1.8g克,膳食纤维 0.9g,钾65mg,钠0.2mg,磷14mg,镁5mg,铁0.1mg,抗坏血酸27mg,维生素总E0.02mg,核黄素0.01mg,硫胺素0.01mg,尼克酸0.2mg。
研究表明,冬瓜维生素中以抗坏血酸、硫胺素、核黄素及尼克酸含量较高,具防治癌症效果的维生素B1, 在冬瓜子中含量相当丰富;矿质元素有钾、钠、钙、铁、锌、铜、磷、硒等8种,其中含钾量显著高于含钠量,属典型的高钾低钠型蔬菜,对需进食低钠盐食物的肾脏病、高血压、浮肿病患者大有益处,其中元素硒还具有抗癌等多种功能;含有除色氨酸外的8种人体必需氨基酸,谷氨酸和天门冬氨酸含量较高,还含有鸟氨酸和 Y-氨基丁酸以及儿童特需的组氨酸;冬瓜不含脂肪,膳食纤维高达0.8%,营养丰富而且结构合理。
灵芝的作用:
免疫调节作用;
巨噬细胞、T淋巴细胞在免疫系统中有重要作用,巨噬细胞的吞噬作用是机体对抗外来细菌、病毒、真菌及寄生虫的主要防御机制。灵芝制剂可以刺激巨噬细胞吞噬功能,同时也能直接刺激淋巴细胞的增殖,以提高自身免疫能力。
抗肿瘤作用:
临床实验报告指出:灵芝(高浓度灵芝制剂)与化学治疗或放化疗治疗合用时,可减轻化学治疗或放射治疗引起的骨髓抑制、胃肠道损伤和免疫功能抑制,提高患者的生活质量,发挥增效减毒的作用。
清热解毒,保护放化疗损伤作用。
通过对灵芝的抗炎、抗菌作用进行实验观察,结果表明高浓度灵芝制剂对实验性无菌性炎症有明显的抗炎作用,并有一定的抑菌和杀菌作用。同时研究指出高浓度灵芝制剂对放射性损伤的保护作用与其刺激骨髓造血功能相关,它能减轻外周血白细胞的降低,促使白细胞恢复。
镇静和镇痛作用;
灵芝提取物能降低中枢神经系统兴奋性,有明显镇静、抗惊厥的作用。
从灵芝中分离的腺苷能抑制中枢神经,减少自发机械活动,提高痛阈,延长咖啡因导致的失望时间,松弛骨骼肌肉。
营养成分:
含水分、蛋白质、粗纤维、灰分、胡萝卜素、维生素B、维生素c、烟酸、维生素E、钾、钠、钙、镁、铁、锰、锌、铜、磷、硒、肌红蛋白、p一胡萝卜素、海胆烯酮、鸡油菌黄质、磷质、甾醇以及葡萄糖甙、香树脂醇类等。芝含有麦角固醇、有机酸、氨基酸、葡萄糖、多糖类、树脂、甘露醇、生物碱、内酯、香豆精、水溶性蛋白质和多种酶类。
白果果的医疗保健作用。据《本草纲目》记载:“熟食温肺、益气、定喘嗽、缩小便、止白浊;生食降痰、消毒杀虫”。现代科学证明:白果有抗大肠杆菌、白喉杆菌、葡萄球菌、结核杆菌、链球菌的作用。中医素以白果治疗支气管哮喘、慢性气管炎、肺结核、白带、淋浊、遗精等疾病。银杏种仁还有祛斑平皱,治疗疮、癣的作用。咳嗽痰稀患者。
性味归经:性平,味甘苦涩,有小毒;入肺、肾经。
功效主治:敛肺气,定喘嗽,止带浊,缩小便,消毒杀虫。主治哮喘,痰嗽,梦遗,白带,白浊,小儿腹泻,虫积,肠风脏毒,淋病,小便频数,以及疥癣、漆疮、白瘤风等病症。
营养成分:每100克含蛋白质6.4克,脂肪2.4克,碳水化合物36克,粗纤维1.2克,蔗糖52克,还原糖1.1 ,钙10毫克,磷218毫克,铁1毫克,胡萝卜素320微克,核黄素50微克,以及白果醇、白果酚、白果酸等多种成分。
食疗作用:
1.抑菌杀菌:白果中含有的白果酸、白果酚,经实验证明有抑菌和杀菌作用,可用于治疗呼吸道感染性疾病。白果水浸剂对各种真菌有不同程度的抑制作用,可止痒疗癣。
2.祛疾止咳:白果味甘苦涩,具有敛肺气、定喘咳的功效,对于肺病咳嗽、老人虚弱体质的哮喘及各种哮喘痰多者,均有辅助食疗作用。
3,抗涝抑虫:白果外种皮中所含的白果酸及白果酚等,有抗结核杆菌的作用。白果用油浸对结核杆菌有很强的抑制作用,用生菜油浸演的新鲜果实,对改善肺结核病所致的发热、盗汗、咳嗽咯血、食欲不振等症状有一定作用。因此,可用于治疗肺结核。
花椒:
花椒性温,味辛。归脾、胃、肾经,花椒驱寒燥湿之力尤其明显,其归经所对应的脏腑是全身水湿运化的关键,使花椒燥湿更有经络的针对性,其味辛,辛温能散可以散肢体肌肉腠理之寒湿。
食疗组合物中,东北雌性红萝卜、雌性红萝卜缨子、东北雌性红萝卜与雌性红萝卜缨子草木灰、无花果、莲子和罗汉果为君药;灵芝为臣药;冬瓜子、白果为佐药,花椒使药。在这组具有治疗肺癌的食疗组合物配方时首先考虑到主症、病机、治疗目的,运用主次分的明食疗组合物配方,相辅相成,相反相成的综合作用,而且扩大治疗范围,以保证食疗治疗肺癌有特效。在药食同源的基础上,进一步开发产品的功效,打造一款具有特殊医疗用途配方食品,实现高效率生产,降低成本的目的;免疫力低下、寒凉是引发肺癌的一个重要原因,食疗治愈肺癌在我国乃至全世界尚未有同类产品能够快速有效治愈肺癌,肺癌在西医治疗中只能开刀做手术,一是费用高,难以清除微小病灶,其复发率非常高,如果再次复发转移会加快病情导致死亡。二是放疗和化疗虽能有效杀灭肿瘤细胞,但对患者体内正常细胞一定的破坏,三是存在一定的副作用,如脱发、恶心呕吐、食欲不振等不良反应。给肺癌患者带来了极大的痛苦;中医也没有好的治疗办法。本发明的药方是经过约三年的临床研究并做了百例肺癌患者医疗临床资料总结而得到的,使早期的肺癌治愈率提高了百分之百八十左右,服用本发明食疗组合物30天癌症理化五项指标全面下降。
具体实施方式:
一种具有治疗肺癌食疗组合物,按照重量份包括以下组分:雌性红萝卜16~30份,雌性红萝卜缨子16~30份,雌性红萝卜与雌性红萝卜缨子草木灰16~30份,无花果3~10份,莲子5~10份,罗汉果4~15份,冬瓜子3~5份,灵芝4~8份,白果1~5份,花椒2~4份。
雌性红萝卜与雌性红萝卜缨子草木灰中雌性红萝卜与雌性红萝卜缨子的最优质量比为1:1,适用范围在质量比为(1~1.2):(1~4)。
所述的食疗组合物添加药学上可接受的辅料制成压片糖果或丸剂。
所述的辅料为乳糖醇、微晶纤维素或低聚果糖醇。
所述的具有治疗肺癌食疗组合物的制备方法,该制备方法包括如下步骤:
步骤一:选材:雌性红萝卜选用由沈阳绿星大白菜研究所出品的“雄性不育系”三系杂交雌性红萝卜;雌性红萝卜缨子采用沈阳绿星大白菜研究所出品的“雄性不育系”三系杂交雌性红萝卜缨子。
步骤二:将雌性红萝卜和雌性红萝卜缨子进行混合冷冻,得到雌性红萝卜和雌性红萝卜缨子混合的粉末颗粒。
步骤三:物料处理:将无花果、灵芝分别粉碎、过筛;将白果、冬瓜子一起炒制,炒制后再粉碎;将莲子、花椒、罗汉果的果肉和果壳一起加水煮制成粘稠状液体,取出莲子、罗汉果果肉进行初次蒸制,莲子变软,碾碎后并放回粘稠状液体中,再用少量水对罗汉果果肉和花椒进行二次煮制,煮制后去掉花椒;二次煮制的水在步骤四中如果在搅拌过程中发现水过多,可以留在下一批物料混合中使用,根据混合需要的水量进行调节,物料混合后成面团形状即可。
步骤三中将白果和冬瓜子炒制,选择温度在120~150℃,时间一般是0.5~1.5h;一是为了去除多余的水分,二是将白果和冬瓜子的油脂析出,使整个食疗组合物的口味更好。
莲子、罗汉果口味偏甜和软糯,水煮后莲子软糯,罗汉果果肉变软,方便后续混合后成面团状,在保持莲子和罗汉果的功效和作用的同时有一定的糯性。花椒味辛,花椒壳不易消化,煮后辛味留在粘稠液体中,将花椒壳直接去除。
为保留无花果和灵芝的功效和作用,直接粉碎加入到粘稠状液体中,混合均匀。
其中,文火温度控制在120~150℃,武火温度控制在180~200℃。
步骤四:物料混合:边搅拌边将炒制后的白果和冬瓜子粉末加入粘稠状液体中,并将软烂的罗汉果果肉和二次煮制的水以及粉碎后的无花果、灵芝的加入进去,继续搅拌,加入雌性红萝卜与雌性红萝卜缨子草木灰,再将雌性红萝卜和雌性红萝卜缨子混合的粉末颗粒缓慢加入,充分搅拌均匀,得到面团状组合物。
步骤五:压制成片或丸剂:将步骤四中的面团状组合物加入乳糖醇、微晶纤维素和低聚果糖醇,及面团状组合物重量0.1%~5%的硬脂酸镁,混合均匀压片,得到压片;其中乳糖醇、微晶纤维素和低聚果糖醇加入的质量按照现有的加入量即可。
丸剂:将步骤四中的面团状组合物掺入适量蜂蜜,组合物和蜂蜜是1:(1~2)的质量比,搓丸,得到丸剂。
步骤二中的制备雌性红萝卜和雌性红萝卜缨子的混合粉末颗粒的具体方法是:
步骤1:混合:将雌性红萝卜和雌性红萝卜缨子进行粉碎,混合,混合均匀后,将混合均匀的物料溶于200~500份纯化水中,同时进行超声处理,使各组分均匀分布在溶液中,得到混合溶液;该混合溶液存在一定的浑浊状态,为雌性红萝卜和雌性红萝卜缨子的纤维等,不需要取出渣质,将其保留在混合溶液中,一方面无需多一道过滤工序,节省成本;另一方面,该渣质中含有一定量的萝卜硫素是本发明食疗组合物的有效成分之一。
步骤2:喷雾:将步骤1的混合溶液在流量3~10mL/min的条件下进行喷雾,得到的小雾滴直接进入液氮中固化,通过抽真空装置收集小雾滴至冷冻室;该方法通过冷冻技术将雌性红萝卜和雌性红萝卜缨子中的有效成分最大程度上的保留,例如,萝卜硫素含量随着温度(60℃以上)的增加会明显减少,所以本发明未使用高温干燥等方法,使用本发明的方法最大程度上保存的雌性红萝卜和雌性红萝卜缨子中的有效成分,减少流失。
步骤3:冷冻干燥:放入冷冻室,冷冻后直接收集失水的粉末颗粒,得到雌性红萝卜和雌性红萝卜缨子的混合粉末颗粒。
步骤1中的超声处理将频率高于20kHz以上的超声波功率控制在5~200W,超声时间是0.5~3h;步骤3的冷冻时间是2~15h,冷冻干燥压力为1~3kPa,温度为-50~-140℃。
上述制备制备雌性红萝卜和雌性红萝卜缨子的混合粉末颗粒的方法优点是:1.采用低温干燥,使雌性红萝卜和雌性红萝卜缨子中的挥发性成分和受热变性的营养成分和芳香成分损失很小,最大程度上保留有效成分;2. 能除去雌性红萝卜和雌性红萝卜缨子中95%~99.5%的水分,保存期长;3.在低温下干燥,不会使蛋白质和酶产生变性,但可使微生物等失去生物活力。
步骤3的冷冻时间、压力和温度可以是呈阶梯变化的,例如,冷冻时间为5小时,那么前2小时的冷冻温度可以是-135℃,冷冻干燥压力是2kPa,然后到5小时冷冻温度上升至-80℃,冷冻干燥压力是1kPa,或者分为三个或更多阶段。该处理方法主要的依据是冷冻时的混合粉末颗粒状态,主要是减少混合粉末颗粒中的含水量,同时保持有效组分,包括萝卜硫素和维生素等。
步骤三中的无花果、灵芝的粉碎后过300~1000目筛;白果、冬瓜子采用文火炒制,到白果和冬瓜子表面焦黄,炒制后粉碎过300~1000目筛;莲子、花椒、罗汉果果肉和果壳与加水量的质量比为1:(2~4),先武火后文火,武火煮至微沸转为文火,文火时随时搅拌,防止后续水减少导致药品糊锅,损失药效,煮至粘稠状液体,使体积减少为原来的一半以上;莲子、罗汉果果肉的初次蒸制采用武火进行快蒸15~30min,罗汉果果肉和花椒二次煮制采用文火慢煮2~10小时,至罗汉果果肉软烂为止,二次煮制时用水量与罗汉果肉的质量相等,在煮制过程中水量会减少,此时不需要再添加水,注意罗汉果肉不要与容器底部长时间接触。
步骤四的雌性红萝卜缨子草木灰的具体制备方法是:选用清洗、晾干后的雌性红萝卜与雌性红萝卜缨子置于高温炉中在800~1000℃下保温1~5h。为了保证高温中的燃烧充分,在保温过程中进行通氧气,使高温炉中的通氧气量在0.5~0.7psi即可。
步骤四的充分搅拌均匀的搅拌速率是50~800r/min,搅拌时间是1h~5h。
实施例1
具有治疗肺癌食疗组合物,按照重量份包括以下组分:雌性红萝卜25份,雌性红萝卜缨子25份,雌性红萝卜与雌性红萝卜缨子草木灰25份,无花果6份,莲子5份,罗汉果8份,冬瓜子5份,灵芝5份,白果3份,花椒3份。其中雌性红萝卜与雌性红萝卜缨子草木灰中雌性红萝卜与雌性红萝卜缨子的质量比为1:1。
该具有治疗肺癌食疗组合物的制备方法包括如下步骤
步骤一:选材:雌性红萝卜选用由沈阳绿星大白菜研究所出品的“雄性不育系”三系杂交雌性红萝卜;雌性红萝卜缨子采用沈阳绿星大白菜研究所出品的“雄性不育系”三系杂交雌性红萝卜缨子;
步骤二:将雌性红萝卜和雌性红萝卜缨子进行混合冷冻,得到雌性红萝卜和雌性红萝卜缨子混合的粉末颗粒;
步骤三:物料处理:将无花果、灵芝分别粉碎、过筛;将白果、冬瓜子一起炒制,炒制后再粉碎;将莲子、花椒、罗汉果的果肉和果壳一起加水煮制成粘稠状液体,取出莲子、罗汉果果肉进行初次蒸制,莲子变软,碾碎后并放回粘稠状液体中,再用少量水对罗汉果果肉和花椒进行二次煮制,煮制后去掉花椒;步骤三中的组分含量按照本实施例所述的食疗组合物质量比进行添加。
步骤三中的无花果、灵芝的粉碎后过1000目筛;白果、冬瓜子采用文火炒制,到白果和冬瓜子表面焦黄,炒制后粉碎过1000目筛;莲子、花椒、罗汉果果肉和果壳与加水量的质量比为1:2先武火后文火,文火时随时搅拌,防止后续水减少导致药品糊锅,损失药效,煮至粘稠状液体,使体积减少为原来的一半以上;莲子、罗汉果果肉的初次蒸制采用武火进行快蒸30min,罗汉果果肉和花椒二次煮制采用文火慢煮8小时,至罗汉果果肉软烂为止,二次煮制时用水量与罗汉果肉的质量相等,在煮制过程中水量会减少,此时不需要再添加水,注意罗汉果肉不要与容器底部长时间接触。
步骤四:物料混合:边搅拌边将炒制后的白果和冬瓜子粉末加入粘稠状液体中,并将软烂的罗汉果果肉和二次煮制的水以及粉碎后的无花果、灵芝的加入进去,继续搅拌,再加入雌性红萝卜与雌性红萝卜缨子草木灰,最后将雌性红萝卜和雌性红萝卜缨子混合的粉末颗粒缓慢加入,充分搅拌均匀,搅拌速率是200r/min,搅拌时间是2h;得到面团状组合物;
步骤四的雌性红萝卜与雌性红萝卜缨子草木灰的具体制备方法是:选用清洗、晾干后的雌性红萝卜与雌性红萝卜缨子置于高温炉中在800℃下保温1h。
步骤五:压制成片或丸剂:将步骤四中的面团状组合物加入乳糖醇10份、微晶纤维素8份和低聚果糖醇8份,及面团状组合物重量3%的硬脂酸镁,混合均匀压片,得到压片;
丸剂:将步骤四中的面团状组合物掺入适量蜂蜜,组合物和蜂蜜是1:1.5的质量比,搓丸,得到丸剂。
步骤二中的雌性红萝卜和雌性红萝卜缨子粉末颗粒的具体制备方法是:
步骤1:混合:将雌性红萝卜和雌性红萝卜缨子进行粉碎,混合,混合均匀后,将混合均匀的物料溶于300份纯化水中,同时进行超声处理,使各组分均匀分布在溶液中,得到混合溶液;
步骤2:喷雾:将步骤1的混合溶液在流量5 mL/min的条件下进行喷雾,得到的小雾滴直接进入液氮中固化,通过抽真空装置收集小雾滴至冷冻室;
步骤3:冷冻干燥:放入冷冻室,冷冻后直接收集失水的粉末颗粒,得到雌性红萝卜和雌性红萝卜缨子的混合粉末颗粒。
步骤1中的超声处理将频率高于20kHz以上的超声波功率控制在10W,超声时间是2h;步骤3的冷冻时间是10h,冷冻干燥压力为1kPa,温度为-135℃。
实施例2
具有治疗肺癌食疗组合物,按照重量份包括以下组分:雌性红萝卜30份,雌性红萝卜缨子30份,雌性红萝卜与雌性红萝卜缨子草木灰30份,无花果4份,莲子6份,罗汉果5份,冬瓜子4份,灵芝5份,白果2份,花椒2份。其中雌性红萝卜与雌性红萝卜缨子草木灰中雌性红萝卜与雌性红萝卜缨子的质量比为1.0:4。
具有治疗肺癌食疗组合物的制备方法是:
步骤一:选材:雌性红萝卜选用由沈阳绿星大白菜研究所出品的“雄性不育系”三系杂交雌性红萝卜;雌性红萝卜缨子采用沈阳绿星大白菜研究所出品的“雄性不育系”三系杂交雌性红萝卜缨子;
步骤二:将雌性红萝卜和雌性红萝卜缨子进行混合冷冻,得到雌性红萝卜和雌性红萝卜缨子混合的粉末颗粒;
步骤三:物料处理:将无花果、灵芝分别粉碎、过筛;将白果、冬瓜子一起炒制,炒制后再粉碎;将莲子、花椒、罗汉果的果肉和果壳一起加水煮制成粘稠状液体,取出莲子、罗汉果果肉进行初次蒸制,莲子变软,碾碎后并放回粘稠状液体中,再用少量水对罗汉果果肉和花椒进行二次煮制,煮制后去掉花椒;
步骤四:物料混合:边搅拌边将炒制后的白果和冬瓜子粉末加入粘稠状液体中,并将软烂的罗汉果果肉和二次煮制的水以及粉碎后的无花果、灵芝的加入进去,继续搅拌,再加入雌性红萝卜与雌性红萝卜缨子草木灰,最后将雌性红萝卜和雌性红萝卜缨子混合的粉末颗粒缓慢加入,充分搅拌均匀,搅拌速率是50~800r/min,搅拌时间是1h~5h;得到面团状组合物;
步骤四的雌性红萝卜与雌性红萝卜缨子草木灰的具体制备方法是:选用清洗、晾干后的雌性红萝卜与雌性红萝卜缨子置于高温炉中在800℃下保温2h。
步骤五:压制成片或丸剂:将步骤四中的面团状组合物加入乳糖醇12份、微晶纤维素10份和低聚果糖醇10份,及面团状组合物重量4%的硬脂酸镁,混合均匀压片,得到压片;
丸剂:将步骤四中的面团状组合物掺入适量蜂蜜,组合物和蜂蜜是1:2的质量比,搓丸,得到丸剂。
步骤二中的具体方法是:
步骤1:混合:将雌性红萝卜和雌性红萝卜缨子进行粉碎,混合,混合均匀后,将混合均匀的物料溶于300份纯化水中,同时进行超声处理,步骤1中的超声处理将频率高于20kHz以上的超声波功率控制在20W,超声时间是1h;使各组分均匀分布在溶液中,得到混合溶液;
步骤2:喷雾:将步骤1的混合溶液在流量5mL/min的条件下进行喷雾,得到的小雾滴直接进入液氮中固化,通过抽真空装置收集小雾滴至冷冻室;
步骤3:冷冻干燥:放入冷冻室,步骤3的冷冻时间是10h,冷冻干燥压力为2kPa,温度为-135℃。冷冻后直接收集失水的粉末颗粒,得到雌性红萝卜和雌性红萝卜缨子的混合粉末颗粒。
步骤三中的无花果、灵芝的粉碎后过1000目筛;白果、冬瓜子采用文火炒制,到白果和冬瓜子表面焦黄,炒制后粉碎过1000目筛;莲子、花椒、罗汉果果肉和果壳与加水量的质量比为1:2先武火后文火,文火时随时搅拌,防止后续水减少导致药品糊锅,损失药效,煮至粘稠状液体,使体积减少为原来的一半以上;莲子、罗汉果果肉的初次蒸制采用武火进行快蒸30min,罗汉果果肉和花椒二次煮制采用文火慢煮5小时,至罗汉果果肉软烂为止,二次煮制时用水量与罗汉果肉的质量相等,在煮制过程中水量会减少,此时不需要再添加水,注意罗汉果肉不要与容器底部长时间接触。
实施例3
具有治疗肺癌食疗组合物,按照重量份包括以下组分:雌性红萝卜16份,雌性红萝卜缨子16份,雌性红萝卜与雌性红萝卜缨子草木灰16份,无花果3份,莲子6份,罗汉果4份,冬瓜子3份,灵芝3份,白果5份,花椒2份。其中雌性红萝卜与雌性红萝卜缨子草木灰中雌性红萝卜与雌性红萝卜缨子的质量比为1:2。
具有治疗肺癌食疗组合物的制备方法:
步骤一:选材:雌性红萝卜选用由沈阳绿星大白菜研究所出品的“雄性不育系”三系杂交雌性红萝卜;雌性红萝卜缨子采用沈阳绿星大白菜研究所出品的“雄性不育系”三系杂交雌性红萝卜缨子;
步骤二:将雌性红萝卜和雌性红萝卜缨子进行混合冷冻,得到雌性红萝卜和雌性红萝卜缨子混合的粉末颗粒;
步骤三:物料处理:将无花果、灵芝分别粉碎、过筛;将白果、冬瓜子一起炒制,炒制后再粉碎;将莲子、花椒、罗汉果的果肉和果壳一起加水煮制成粘稠状液体,取出莲子、罗汉果果肉进行初次蒸制,莲子变软,碾碎后并放回粘稠状液体中,再用少量水对罗汉果果肉和花椒进行二次煮制,煮制后去掉花椒;
步骤四:物料混合:边搅拌边将炒制后的白果和冬瓜子粉末加入粘稠状液体中,并将软烂的罗汉果果肉和二次煮制的水以及粉碎后的无花果、灵芝的加入进去,继续搅拌,再加入雌性红萝卜与雌性红萝卜缨子草木灰,最后将雌性红萝卜和雌性红萝卜缨子混合的粉末颗粒缓慢加入,充分搅拌均匀,搅拌速率是50r/min,搅拌时间是5h;得到面团状组合物;
步骤四的雌性红萝卜与雌性红萝卜缨子草木灰的具体制备方法是:选用清洗、晾干后的雌性红萝卜与雌性红萝卜缨子置于高温炉中在1000℃下保温1h。
步骤五:压制成片或丸剂:将步骤四中的面团状组合物加入乳糖醇8份、微晶纤维素6份和低聚果糖醇6份,及面团状组合物重量0.1%的硬脂酸镁,混合均匀压片,得到压片;
丸剂:将步骤四中的面团状组合物掺入适量蜂蜜,组合物和蜂蜜是1:1.5的质量比,搓丸,得到丸剂。
步骤二中的具体方法是:
步骤1:混合:将雌性红萝卜和雌性红萝卜缨子进行粉碎,混合,混合均匀后,将混合均匀的物料溶于200份纯化水中,同时进行超声处理,使各组分均匀分布在溶液中,得到混合溶液;
步骤2:喷雾:将步骤1的混合溶液在流量3mL/min的条件下进行喷雾,得到的小雾滴直接进入液氮中固化,通过抽真空装置收集小雾滴至冷冻室;
步骤3:冷冻干燥:放入冷冻室,冷冻后直接收集失水的粉末颗粒,得到雌性红萝卜和雌性红萝卜缨子的混合粉末颗粒。
步骤1中的超声处理将频率高于20kHz以上的超声波功率控制在5W,超声时间是3h;步骤3的冷冻时间是15h,冷冻干燥压力为3kPa,温度为-50℃。
步骤三中的无花果、灵芝的粉碎后过300目筛;白果、冬瓜子采用文火炒制,到白果和冬瓜子表面焦黄,炒制后粉碎过300目筛;莲子、花椒、罗汉果果肉和果壳与加水量的质量比为1:4先武火后文火,煮至粘稠状液体,使体积减少为原来的一半以上;莲子、罗汉果果肉的初次蒸制采用武火进行快蒸15~30min,罗汉果果肉和花椒二次煮制采用文火慢煮2小时,至罗汉果果肉软烂为止,二次煮制时用水量与罗汉果肉的质量相等,在煮制过程中水量会减少,此时不需要再添加水,注意罗汉果肉不要与容器底部长时间接触。
实施例4
具有治疗肺癌食疗组合物,按照重量份包括以下组分:雌性红萝卜30份,雌性红萝卜缨子30份,雌性红萝卜与雌性红萝卜缨子草木灰30份,无花果10份,莲子10份,罗汉果15份,冬瓜子3份,灵芝8份,白果1份,花椒4份。其中雌性红萝卜与雌性红萝卜缨子草木灰中雌性红萝卜与雌性红萝卜缨子的质量比为1.2:1。
具有治疗肺癌食疗组合物的制备方法:
步骤一:选材:雌性红萝卜选用由沈阳绿星大白菜研究所出品的“雄性不育系”三系杂交雌性红萝卜;雌性红萝卜缨子采用沈阳绿星大白菜研究所出品的“雄性不育系”三系杂交雌性红萝卜缨子;
步骤二:将雌性红萝卜和雌性红萝卜缨子进行混合冷冻,得到雌性红萝卜和雌性红萝卜缨子混合的粉末颗粒;
步骤三:物料处理:将无花果、灵芝分别粉碎、过筛;将白果、冬瓜子一起炒制,炒制后再粉碎;将莲子、花椒、罗汉果的果肉和果壳一起加水煮制成粘稠状液体,取出莲子、罗汉果果肉进行初次蒸制,莲子变软,碾碎后并放回粘稠状液体中,再用少量水对罗汉果果肉和花椒进行二次煮制,煮制后去掉花椒;
步骤四:物料混合:边搅拌边将炒制后的白果和冬瓜子粉末加入粘稠状液体中,并将软烂的罗汉果果肉和二次煮制的水以及粉碎后的无花果、灵芝的加入进去,继续搅拌,再加入雌性红萝卜与雌性红萝卜缨子草木灰,最后将雌性红萝卜和雌性红萝卜缨子混合的粉末颗粒缓慢加入,充分搅拌均匀,搅拌速率是800r/min,搅拌时间是1h;得到面团状组合物;
步骤四的雌性红萝卜与雌性红萝卜缨子草木灰的具体制备方法是:选用清洗、晾干后的雌性红萝卜与雌性红萝卜缨子置于高温炉中在800℃下保温5h。
步骤五:压制成片或丸剂:将步骤四中的面团状组合物加入乳糖醇14份、微晶纤维素12份和低聚果糖醇14份,及面团状组合物重量5%的硬脂酸镁,混合均匀压片,得到压片;
丸剂:将步骤四中的面团状组合物掺入适量蜂蜜,组合物和蜂蜜是1:1.5的质量比,搓丸,得到丸剂。
步骤二中的具体方法是:
步骤1:混合:将雌性红萝卜和雌性红萝卜缨子进行粉碎,混合,混合均匀后,将混合均匀的物料溶于500份纯化水中,同时进行超声处理,使各组分均匀分布在溶液中,得到混合溶液;
步骤2:喷雾:将步骤1的混合溶液在流量10mL/min的条件下进行喷雾,得到的小雾滴直接进入液氮中固化,通过抽真空装置收集小雾滴至冷冻室;
步骤3:冷冻干燥:放入冷冻室,冷冻后直接收集失水的粉末颗粒,得到雌性红萝卜和雌性红萝卜缨子的混合粉末颗粒。
步骤1中的超声处理将频率高于20kHz以上的超声波功率控制在100W,超声时间是0.5h;步骤3的冷冻时间是2h,冷冻干燥压力为1kPa,温度为-140℃。
步骤三中的无花果、灵芝的粉碎后过800目筛;白果、冬瓜子采用文火炒制,到白果和冬瓜子表面焦黄,炒制后粉碎过800目筛;莲子、花椒、罗汉果果肉和果壳与加水量的质量比为1:2先武火后文火,文火时随时搅拌,防止后续水减少导致药品糊锅,损失药效,煮至粘稠状液体,使体积减少为原来的一半以上;莲子、罗汉果果肉的初次蒸制采用武火进行快蒸15~30min,罗汉果果肉和花椒二次煮制采用文火慢煮10小时,至罗汉果果肉软烂为止,二次煮制时用水量与罗汉果肉的质量相等,在煮制过程中水量会减少,此时不需要再添加水,注意罗汉果肉不要与容器底部长时间接触。
临床数据:
采用本发明具有治疗肺癌食疗组合物进行临床给药,采集肺癌患者共102例,其中肺癌早期11例,肺癌中期24例,肺癌晚期67例,并观察不使用本发明的食疗组合物作为空白组10例,以及仅食用雌性红萝卜冻干粉和雌性红萝卜缨子冻干的肺癌患者10例。
肺癌早期患者按照食疗组合物食用3个月以上症状有明显减轻和改善。其中,对于早期肺癌的声音沙哑,吞咽困难,咳嗽,胸痛肩背痛均有明显的缓解,肺癌肿块从2厘米左右减小至1.3~1.6厘米左右,对于早期肺癌有明显改善,配合现有的肺癌手术治愈率可达百分之九十以上。优点是稳定患者病情,提高生存质量,可以有效控制癌细胞生长,能够增强机体免疫功能,病情可以快速好转。
中期肺癌患者按照食疗组合物食用5个月后症状有明显减轻和改善。其中,对于中期肺癌的胸痛,声音嘶哑,胸腔积液、气促等症状均有明显的缓解,肺癌肿块从4厘米左右减小至3.2~3.5厘米左右,对于肺癌患者的不适症状有明显的改善,起到了稳定患者病情、延长生存期、提高生存质量、有效控制癌细胞生长、增强机体免疫功能等作用。
晚期肺癌患者长期、多次使用本发明的食疗组合物,对于晚期肺癌患者的剧烈疼痛和咳嗽均有减轻,有效控制肺癌肿块大小,延长生存期。
对于空白组未采用本发明的食疗组合物,同等时间内,除进行手术外,肺癌肿块大小未见明显变化或者肿块变大。
对于仅食用雌性红萝卜冻干粉和雌性红萝卜缨子冻干粉的肺癌患者,早期肺癌患者食用6个月后,有一定程度的减轻,但肺癌肿块有减小,但不明显。对于中期肺癌患者,食用超过8个月后对肺癌症状有一定减轻,但肺癌肿块无明显变化,还需通过其他治疗。对于晚期肺癌患者,将食用次数和时间延长数倍,仅有一定症状减轻。
通过上述临床数据可知,仅食用雌性红萝卜冻干粉和雌性红萝卜缨子冻干粉的作用要明显小于采用本发明的食疗组合物,由此可见,本食疗组合物将雌性红萝卜与雌性红萝卜缨子草木灰、雌性红萝卜和雌性红萝卜缨子混合的粉末颗粒与无花果、莲子、罗汉果、冬瓜子、灵芝、白果和花椒相结合,使抗癌功效发挥更好。
典型病例:
以下病例均为诸多临床病例中最具有代表性的病例,并不限定为本发明所限定的护范围。
病例1。肺癌晚期个体化医治,患者男性,61岁,因"声音沙哑、吞咽艰苦1月余,恶心、呕吐3天"入院。1月前外院CT示左下肺占位、纵隔淋巴结肿大;脑核磁示多发转移瘤;支气管镜活检:恶性肿瘤不除外。治疗前胸部CT示左肺下叶基底段占宏大占位,脑核磁是多发性脑转移;采用本发明食疗组合物与现有的抗癌手段治疗三个疗程后,肺部肿物较前缩小,脑转移灶局部缩小;持续采用双特异性免疫治疗技术治疗三疗程后,肺部病灶进一步缩小,脑转移灶完整消散。
病例2。肺癌患者,男,58岁, 1年前无明显诱因出现上胸部痛,间歇性无规律,为隐痛可耐受,不向它处放射,胸骨有压痛,咳嗽,深呼吸时不加重,无劳累后气促,胸闷不伴呼吸困难,于当地医院行胸片等检查,未发现明显异常也未进行治疗。
1月前出现背痛,左大腿痛,疼痛性质同前,并伴左腹股沟淋巴结痛,局部无红肿,并渐出现咳嗽、咳痰,次数不多,痰少,为白色粘液痰。当地市医院就诊,查胸片示慢性血行播散性肺结核,肺内转移性病变不排除;CT示:双肺广泛结节性病灶。SPECT示:全身骨多处骨质代谢异常,恶性可能性大。
两个疗程后复查结果:
肿瘤标志物:糖链抗原19-9:74→25(正常值:8.4±7.4kU/L)、癌胚抗原:83.4→20(≤5ng/ml)、糖链抗原242:22.83→15.29(<12kU/L)、铁蛋白416.89→256.1(男性80-130ng/ml)。
治疗前后SPECT检查结果对比:肋骨、胸骨、脊椎骨、骨盆骨等处多个显像剂分布异常增高区与治疗前对比面积明显缩小。
治疗前后CT扫描结果对比:原左肺下叶背段的软组织肿块缩小,纵隔内见增大的淋巴结数目减少。
病例3。男,37岁。咳嗽、头痛、发热14天。体检无阳性体征。胸部X线片及胸部CT示右肺上叶占位病变,头颅CT未发现异常。
见肿块位于右肺上叶尖后段,大小3cm×6cm×7cm,质地中等,肿块与胸壁紧密粘连,行右肺上叶切除术。术前和术后配合使用食疗组合物。
治疗效果:经治疗3个月,体温正常,神志清楚,头痛消失,无神经系统后遗症,脑脊液检查隐球菌阴性,痊愈出院。
病例4。男,年初咳嗽数月,伴声音嘶哑,未予重视,年中时分症状进行性加重,遂到医院行CT检查示:左肺占位,中心性肺癌可能性大,后MRI检查提示:肺癌。伴肝脏广泛转移。给予抗炎,保肝治疗。
治疗前症见:咳嗽,声音嘶哑,低热盗汗,上腹疼痛不适,舌质暗苔白厚腻,脉细数。
治疗中:该名患者出现了肝转移的症状,因此不能手术,进行3个疗程配合食疗组合物治疗。放射治疗的目的是尽可能地消融局部肿大的癌肿,还能快速准确杀灭全身的癌细胞,提高患者免疫力,全面改善患者的精神状况和一般状况,最后让患者实现带瘤生存。
治疗后:经数月治疗,患者精神好,无盗汗,上腹疼痛明显减轻,食欲尚佳,癌细胞扩散得到有效控制,患者的精神状态转好,症状明显减轻。
病例5。女,86岁,肺癌晚期,在彭州同一医院检验中五项指标在服用本发明的食疗组合物前后如下表1所示,
表1 使用前后五项指标的数据对比
检测项目 | 使用前指标 | 使用后指标 |
癌胚抗原/CEA | 3.26 | 2.01 |
甲胎蛋白/AFP | 4.57 | 3.02 |
糖类抗原CA-125 | 40.21 | 13.10 |
糖类抗原CA-153 | 86.43 | 38.54 |
糖类抗原CA19-9 | 11.10 | 10.44 |
从表1中可以看出,五项指标均有明显下降。患者服用食疗组合物前无法下床,身体疼痛难忍,已三天未正常进食,服用食疗组合物数月后逐渐可以正常进食,并且疼痛症状明显减轻。
以上仅为本发明的具体实施例和临床数据,并不用于限制本发明,对于本领域的技术人员来说,本发明可以有各种更改和变化。凡在本发明的精神和原则之内,所作的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。
Claims (10)
1.一种具有治疗肺癌食疗组合物,其特征在于:按照重量份包括以下组分:雌性红萝卜16~30份,雌性红萝卜缨子16~30份,雌性红萝卜与雌性红萝卜缨子草木灰16~30份,无花果3~10份,莲子5~10份,罗汉果4~15份,冬瓜子3~5份,灵芝4~8份,白果1~5份,花椒2~4份。
2.根据权利要求1所述的具有治疗肺癌食疗组合物,其特征在于:按照重量份包括以下组分:雌性红萝卜25份,雌性红萝卜缨子25份,雌性红萝卜与雌性红萝卜缨子草木灰25份,无花果6份,莲子5份,罗汉果8份,冬瓜子5份,灵芝5份,白果3份,花椒3份。
3.根据权利要求1所述的具有治疗肺癌食疗组合物,其特征在于:按照重量份包括以下组分:雌性红萝卜30份,雌性红萝卜缨子30份,雌性红萝卜与雌性红萝卜缨子草木灰30份,无花果4份,莲子6份,罗汉果5份,冬瓜子4份,灵芝5份,白果2份,花椒2份。
4.根据权利要求1~3任一所述的具有治疗肺癌食疗组合物,其特征在于, 所述的食疗组合物添加药学上可接受的辅料制成压片或丸剂;所述的辅料为乳糖醇、微晶纤维素或低聚果糖醇。
5.根据权利要求1所述的具有治疗肺癌食疗组合物的制备方法,其特征在于:该制备方法包括如下步骤:
步骤一:选材:雌性红萝卜选用由沈阳绿星大白菜研究所出品的“雄性不育系”三系杂交雌性红萝卜;雌性红萝卜缨子采用沈阳绿星大白菜研究所出品的“雄性不育系”三系杂交雌性红萝卜缨子;
步骤二:制成混合粉末颗粒:将雌性红萝卜和雌性红萝卜缨子进行混合冷冻,得到雌性红萝卜和雌性红萝卜缨子混合的粉末颗粒;
步骤三:物料处理:将无花果、灵芝分别粉碎、过筛;将白果、冬瓜子一起炒制,炒制后再粉碎;将莲子、花椒、罗汉果的果肉和果壳一起加水煮制成粘稠状液体,取出莲子、罗汉果果肉进行初次蒸制,莲子变软,碾碎后并放回粘稠状液体中,再用少量水对罗汉果果肉和花椒进行二次煮制,煮制后去掉花椒;
步骤四:物料混合:边搅拌边将炒制后的白果和冬瓜子粉末加入粘稠状液体中,并将软烂的罗汉果果肉和二次煮制的水以及粉碎后的无花果、灵芝的加入进去,继续搅拌,再加入雌性红萝卜与雌性红萝卜缨子草木灰,最后将雌性红萝卜和雌性红萝卜缨子混合的粉末颗粒缓慢加入,充分搅拌均匀,得到面团状组合物;
步骤五:压制成片或丸剂:将步骤四中的面团状组合物加入乳糖醇、微晶纤维素和低聚果糖醇,及面团状组合物重量0.1%~5%的硬脂酸镁,混合均匀压片,得到压片;
丸剂:将步骤四中的面团状组合物掺入适量蜂蜜,搓丸,得到丸剂。
6.根据权利要求5所述的具有治疗肺癌食疗组合物的制备方法,其特征在于:步骤二中的具体方法是:
步骤1:混合:将雌性红萝卜和雌性红萝卜缨子进行粉碎,混合,混合均匀后,将混合均匀的物料溶于200~500份纯化水中,同时进行超声处理,使各组分均匀分布在溶液中,得到混合溶液;
步骤2:喷雾:将步骤1的混合溶液在流量3~10mL/min的条件下进行喷雾,得到的小雾滴直接进入液氮中固化,通过抽真空装置收集小雾滴至冷冻室;
步骤3:冷冻干燥:放入冷冻室,冷冻后直接收集失水的粉末颗粒,得到雌性红萝卜和雌性红萝卜缨子的混合粉末颗粒。
7.根据权利要求6所述的具有治疗肺癌食疗组合物的制备方法,其特征在于:步骤1中的超声处理将频率高于20kHz以上的超声波功率控制在5~200W,超声时间是0.5~3h;步骤3的冷冻时间是2~15h,冷冻干燥压力为1~3kPa,温度为-50~-140℃。
8.根据权利要求5所述的具有治疗肺癌食疗组合物的制备方法,其特征在于:步骤三中的无花果、灵芝的粉碎后过300~1000目筛;白果、冬瓜子采用文火炒制,到白果和冬瓜子表面焦黄,炒制后粉碎过300~1000目筛;莲子、花椒、罗汉果果肉和果壳与加水量的质量比为1:(2~4)先武火后文火煮至粘稠状液体,使体积减少为原来的一半以上;莲子、罗汉果果肉的初次蒸制采用武火进行快蒸15~30min,罗汉果果肉和花椒二次煮制采用文火慢煮2~10小时,至罗汉果果肉软烂为止,二次煮制时用水量与罗汉果肉的质量相等,在煮制过程中水量会减少。
9.根据权利要求5所述的具有治疗肺癌食疗组合物的制备方法,其特征在于:步骤四的雌性红萝卜与雌性红萝卜缨子草木灰的具体制备方法是:选用清洗、晾干后的雌性红萝卜与雌性红萝卜缨子置于高温炉中在800~1000℃下保温1~5h。
10.根据权利要求5所述的具有治疗肺癌食疗组合物的制备方法,其特征在于:步骤四的充分搅拌均匀的搅拌速率是50~800r/min,搅拌时间是1h~5h。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910326917.3A CN110537684A (zh) | 2019-04-23 | 2019-04-23 | 一种具有治疗肺癌食疗组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910326917.3A CN110537684A (zh) | 2019-04-23 | 2019-04-23 | 一种具有治疗肺癌食疗组合物及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110537684A true CN110537684A (zh) | 2019-12-06 |
Family
ID=68702698
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910326917.3A Pending CN110537684A (zh) | 2019-04-23 | 2019-04-23 | 一种具有治疗肺癌食疗组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110537684A (zh) |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102949679A (zh) * | 2012-12-04 | 2013-03-06 | 周玉娟 | 一种用于治疗肺癌的药物及制备方法 |
CN103766751A (zh) * | 2014-01-24 | 2014-05-07 | 赵杏珍 | 防治雾霾引发的呼吸道疾病及肺癌的药食同膳面 |
CN104187661A (zh) * | 2014-08-23 | 2014-12-10 | 胡安然 | 一种调理肺癌的方便食品 |
CN104771729A (zh) * | 2015-04-03 | 2015-07-15 | 江蕾 | 一种用于肺癌辅助治疗的中药丸剂及制备方法 |
CN105106754A (zh) * | 2015-09-16 | 2015-12-02 | 庄树藩 | 一种食疗抗癌制剂及其制备方法 |
CN106174459A (zh) * | 2015-05-27 | 2016-12-07 | 龚森淼 | 一种预防癌症、治疗癌症的辅助功能食品 |
CN106620518A (zh) * | 2016-09-21 | 2017-05-10 | 深圳市得道中医馆管理有限责任公司 | 一种中药组合物及其制备方法和治疗肺癌的应用 |
CN109329897A (zh) * | 2018-10-19 | 2019-02-15 | 中南大学 | 一种用于癌症的辅助治疗食品组合物及其制备方法 |
CN109481589A (zh) * | 2018-11-02 | 2019-03-19 | 吴保喜 | 一种治疗肺癌的排毒抗癌胶囊及食疗抗癌的制备方法 |
-
2019
- 2019-04-23 CN CN201910326917.3A patent/CN110537684A/zh active Pending
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102949679A (zh) * | 2012-12-04 | 2013-03-06 | 周玉娟 | 一种用于治疗肺癌的药物及制备方法 |
CN103766751A (zh) * | 2014-01-24 | 2014-05-07 | 赵杏珍 | 防治雾霾引发的呼吸道疾病及肺癌的药食同膳面 |
CN104187661A (zh) * | 2014-08-23 | 2014-12-10 | 胡安然 | 一种调理肺癌的方便食品 |
CN104771729A (zh) * | 2015-04-03 | 2015-07-15 | 江蕾 | 一种用于肺癌辅助治疗的中药丸剂及制备方法 |
CN106174459A (zh) * | 2015-05-27 | 2016-12-07 | 龚森淼 | 一种预防癌症、治疗癌症的辅助功能食品 |
CN105106754A (zh) * | 2015-09-16 | 2015-12-02 | 庄树藩 | 一种食疗抗癌制剂及其制备方法 |
CN106620518A (zh) * | 2016-09-21 | 2017-05-10 | 深圳市得道中医馆管理有限责任公司 | 一种中药组合物及其制备方法和治疗肺癌的应用 |
CN109329897A (zh) * | 2018-10-19 | 2019-02-15 | 中南大学 | 一种用于癌症的辅助治疗食品组合物及其制备方法 |
CN109481589A (zh) * | 2018-11-02 | 2019-03-19 | 吴保喜 | 一种治疗肺癌的排毒抗癌胶囊及食疗抗癌的制备方法 |
Non-Patent Citations (1)
Title |
---|
沈阳市抗风红生物技术有限公司: "抗风红东北雌性红萝卜超微原粉(简装)", 《007商务网》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103749982B (zh) | 用于提高产鸡蛋产量的饲料、中药添加剂和制备方法 | |
CN107173694A (zh) | 一种营养全面平衡的全素食代餐粉配方 | |
EP3626249A2 (en) | Traditional chinese medicine healthcare preparation for fat elimination and weight reduction | |
CN102805274B (zh) | 一种0-14日龄小麦型肉小鸭配合饲料及其制备方法 | |
CN103478796A (zh) | 一种野生菌汤料的配方及生产方法 | |
CN104171985A (zh) | 一种均衡营养复合型芽苗健康食品 | |
CN103610153A (zh) | 一种健脾养生汤及其制作方法 | |
CN109497227A (zh) | 一种红糖杞枣保健姜茶 | |
CN111000252A (zh) | 一种减脂且营养均衡的代餐食品及其制备方法 | |
CN105685710A (zh) | 一种防癌降脂醋饮及其制备方法 | |
CN103704568B (zh) | 临床膳食食品 | |
CN109998057A (zh) | 具有增强人体免疫力作用的食疗产品及其制备方法 | |
CN104687133A (zh) | 一种鹿茸补肾虚强身汤料的配方及生产方法 | |
CN112273490A (zh) | 山楂生姜茶饮剂 | |
KR20120066380A (ko) | 사슴뼈의 분말을 이용한 한방 건강보조식품 | |
CN109730222A (zh) | 酵素复合液及其保健饮料 | |
KR20110118911A (ko) | 한약재를 이용한 유산균 곡물 발효 추출물 및 이의 제조방법 | |
CN110537684A (zh) | 一种具有治疗肺癌食疗组合物及其制备方法 | |
CN101971981B (zh) | 用于恶性肿瘤患者术后调养的营养粥 | |
CN111494555A (zh) | 一种药食两用提高人体免疫功能的中药组合物及其制备方法 | |
CN105361149A (zh) | 一种青稞虫草糁子营养粉及其制备方法 | |
CN110679935A (zh) | 一种牛蒡人参精华膏及其制备方法 | |
CN103444930A (zh) | 一种秋季养身下午茶袋泡茶 | |
KR102462817B1 (ko) | 진안홍삼데일리 건강기능식품 조성물의 제조방법 | |
CN109954053A (zh) | 一种具有治疗乳腺癌食疗组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20191206 |